Dr. Barry Dworkin

Genetically engineering T-cell cancer killers for acute lymphoblastic leukemia

Madely Health Headlines Commentary for February 20, 2014

Source:

‘Living drug’ kills leukemia in 88 percent of patients

Reference:

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Related posts:

  1. HIV treatment with modified T cells successful in small study
  2. Genes research offers cancer treatment hope
  3. Proof of concept study demonstrates that you can change pancreatic cells to produce insulin
  4. Judge overrides parents wishes to use cannabis, vitamins, and diet treatments and orders that three-year-old boy continue his chemo treatments for lymphoblastic leukemia. Rate of success from chemo is over 90 per cent with 98 per cent remission in first few weeks of treatment